alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GULFWEST OIL
COMPANY'S  QUARTERLY REPORT FILED ON FORM 10-Q/A FOR THE QUARTER ENDED MARCH 31,
1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1               
<CURRENCY>                    0                
       
<S>                             <C>
<PERIOD-TYPE>                  3-MOS
<FISCAL-YEAR-END>              DEC-31-1996     
<PERIOD-START>                 JAN-1-1997     
<PERIOD-END>                   MAR-31-1997     
<EXCHANGE-RATE>                1               
<CASH>                         66,912                
<SECURITIES>                   0                
<RECEIVABLES>                  1,433,324                
<ALLOWANCES>                   0                
<INVENTORY>                    0                
<CURRENT-ASSETS>               1,608,914                
<PP&E>                         16,237,728                
<DEPRECIATION>                 (1,482,240)                
<TOTAL-ASSETS>                 16,462,097                
<CURRENT-LIABILITIES>          4,559,487                
<BONDS>                        0                
<PREFERRED-MANDATORY>          0                
<PREFERRED>                    46                
<COMMON>                       1,696                
<OTHER-SE>                     3,812,085                
<TOTAL-LIABILITY-AND-EQUITY>   16,462,097                
<SALES>                        1,154,621               
<TOTAL-REVENUES>               1,304,722                
<CGS>                          0                
<TOTAL-COSTS>                  986,084                
<OTHER-EXPENSES>               0                
<LOSS-PROVISION>               0                
<INTEREST-EXPENSE>             (232,914)                
<INCOME-PRETAX>                86,022                
<INCOME-TAX>                   0               
<INCOME-CONTINUING>            86,022                
<DISCONTINUED>                 0                
<EXTRAORDINARY>                0                
<CHANGES>                      0                
<NET-INCOME>                   86,022                
<EPS-PRIMARY>                  (.002)                
<EPS-DILUTED>                  (.002)                
        

</TABLE>
Exhibit 99.3

                                    EXHIBIT B

                                   Resignation

The undersigned hereby resigns from the LaserSight Board of Directors and from
serving, in all capacities, on any committee of the LaserSight Board of
Directors.

      /s/ David J. Pieroni
----------------------------------
David Pieroni

Dated: June 12, 2003
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2995 Luminescent zinc sulfide. ( a ) *Identity.* The color additive luminescent zinc sulfide is zinc sulfide containing a copper activator. Following excitation by daylight or a suitable artificial light, luminescent zinc sulfide produces a yellow-green phosphorescence with a maximum at 530 nanometers.
( b ) *Specifications.* Luminescent zinc sulfide shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Zinc sulfide, not less than 99.8 percent. Copper, 100±5 parts per million. Lead, not more than 20 parts per million. Arsenic, not more than 3 parts per million. Mercury, not more than 1 part per million. Cadmium, not more than 15 parts per million.
( c ) *Uses and restrictions.* The color additive luminescent zinc sulfide may be safely used for coloring externally applied facial makeup preparations and nail polish included under § 720.4(c)(7)(ix) and (c)(8)(v) of this chapter, respectively, to the following restrictions: ( 1 ) The amount of luminescent zinc sulfide in facial makeup preparations shall not exceed 10 percent by weight of the final product.
( 2 ) Facial makeup preparations containing luminescent zinc sulfide are intended for use only on limited, infrequent occasions, e.g., Halloween, and not for regular or daily use.
( d ) *Labeling requirements.* ( 1 ) The label of the color additive and any mixtures prepared therefrom shall bear expiration dates for the sealed and open container (established through generally accepted stability testing methods), other information required by § 70.25 of this chapter, and adequate directions to prepare a final product complying with the limitations prescribed in paragraph (c) of this section.
( 2 ) The label of a facial makeup preparation containing the color additive shall bear, in addition to other information required by the law, the following statement conspicuously displayed: Do not use in the area of the eye.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[65 FR 48377, Aug. 8, 2000; 65 FR 75158, Dec. 1, 2000]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1250 Desoxycorticosterone test system. ( a ) *Identification.* A desoxycorticosterone test system is a device intended to measure desoxycorticosterone (DOC) in plasma and urine. DOC measurements are used in the diagnosis and treatment of patients with hypermineralocorticoidism (excess retention of sodium and loss of potassium) and other disorders of the adrenal gland.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2306, Jan. 14, 2000]
<PAGE>



                        CONSENT OF MARKS SHRON & COMPANY, LLP

We consent to the incorporation by reference in this Amended Annual Report on 
Form 10-K/A, filed with the Securities and Exchange Commission by NHP 
Incorporated (NHP) of our reports dated January 19, 1995 and January 25, 1996 
with respect to the audits of Two Bridges Associates for the years ended 
December 31, 1994 and 1995, and the incorporation by reference of such report 
into NHP's Registration Statement on Form S-8 (No. 333-11933), NHP's 
Registration Statement on Form S-8 (No. 333-11863), NHP's Registration 
Statement on Form S-8 (333-11917), NHP's Registration Statement on Form S-8 
(333-11857) and NHP's Registration Statement on Form S-8 (No.333-08137).

                                            /s/ Marks Shron & Company, LLP

                                            Marks Shron & Company, LLP


Great Neck, New York
October 3, 1997
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7735 Prothrombin-proconvertin test and thrombotest. ( a ) *Identification.* The prothrombin-proconvertin test and thrombotest are devices used in the regulation of coumarin therapy (administration of a coumarin anticoagulant such as sodium warfarin in the treatment of venous thrombosis and pulmonary embolism) and as a diagnostic test in conjunction with, or in place of, the Quick prothrombin time test to detect coagulation disorders.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60626, Sept. 12, 1980, as amended at 84 FR 71800, Dec. 30, 2019]
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               JUN-30-1997
<CASH>                                            2858
<INT-BEARING-DEPOSITS>                           65619
<FED-FUNDS-SOLD>                                  2465
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                       3048
<INVESTMENTS-CARRYING>                           15821
<INVESTMENTS-MARKET>                             15844
<LOANS>                                          63583
<ALLOWANCE>                                        643
<TOTAL-ASSETS>                                   90966
<DEPOSITS>                                       75177
<SHORT-TERM>                                       881
<LIABILITIES-OTHER>                                873
<LONG-TERM>                                       5000
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        963
<OTHER-SE>                                        8072
<TOTAL-LIABILITIES-AND-EQUITY>                   90966
<INTEREST-LOAN>                                   2756
<INTEREST-INVEST>                                  570
<INTEREST-OTHER>                                    34
<INTEREST-TOTAL>                                  3360
<INTEREST-DEPOSIT>                                1299
<INTEREST-EXPENSE>                                1409
<INTEREST-INCOME-NET>                             1951
<LOAN-LOSSES>                                       13
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                   1601
<INCOME-PRETAX>                                    540
<INCOME-PRE-EXTRAORDINARY>                         540
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       352
<EPS-PRIMARY>                                     1.83
<EPS-DILUTED>                                     1.80
<YIELD-ACTUAL>                                    4.92
<LOANS-NON>                                       1174
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                   654
<CHARGE-OFFS>                                       51
<RECOVERIES>                                        27
<ALLOWANCE-CLOSE>                                  643
<ALLOWANCE-DOMESTIC>                               643
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FINANCIAL
STATEMENTS INCLUDED IN FORM 10-QSB AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                         575,157
<SECURITIES>                                         0
<RECEIVABLES>                                2,391,337
<ALLOWANCES>                                         0
<INVENTORY>                                    257,062
<CURRENT-ASSETS>                             3,223,556
<PP&E>                                       1,935,592
<DEPRECIATION>                                 132,867
<TOTAL-ASSETS>                              17,060,077
<CURRENT-LIABILITIES>                        2,334,178
<BONDS>                                      9,000,000
<PREFERRED-MANDATORY>                          739,696
<PREFERRED>                                     28,923
<COMMON>                                     7,597,850
<OTHER-SE>                                 (5,380,570)
<TOTAL-LIABILITY-AND-EQUITY>                17,060,077
<SALES>                                      5,094,672
<TOTAL-REVENUES>                             5,094,672
<CGS>                                        2,461,592
<TOTAL-COSTS>                                2,461,592
<OTHER-EXPENSES>                             1,821,107
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             519,513
<INCOME-PRETAX>                                712,876
<INCOME-TAX>                                   133,929
<INCOME-CONTINUING>                            578,947
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   578,947
<EPS-PRIMARY>                                     1.21
<EPS-DILUTED>                                     1.16
        

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3360 Drug metabolizing enzyme genotyping system. ( a ) *Identification.* A drug metabolizing enzyme genotyping system is a device intended for use in testing deoxyribonucleic acid (DNA) extracted from clinical samples to identify the presence or absence of human genotypic markers encoding a drug metabolizing enzyme. This device is used as an aid in determining treatment choice and individualizing treatment dose for therapeutics that are metabolized primarily by the specific enzyme about which the system provides genotypic information.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Drug Metabolizing Enzyme Genotyping Test System.” See § 862.1(d) for the availability of this guidance document.
[70 FR 11867, Mar. 10, 2005]
<TABLE> <S> <C>

<ARTICLE>           5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THERMO POWER
CORPORATION'S QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED APRIL 3, 1999
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>        1,000
       
<S>                              <C>
<PERIOD-TYPE>                                 6-MOS
<FISCAL-YEAR-END>                             OCT-02-1999
<PERIOD-END>                                  APR-03-1999
<CASH>                                                 15,040
<SECURITIES>                                                0
<RECEIVABLES>                                          65,915
<ALLOWANCES>                                            9,634
<INVENTORY>                                            39,366
<CURRENT-ASSETS>                                      132,441
<PP&E>                                                 34,627
<DEPRECIATION>                                         10,969
<TOTAL-ASSETS>                                        324,369
<CURRENT-LIABILITIES>                                  97,502
<BONDS>                                                   393
<PREFERRED-MANDATORY>                                       0
<PREFERRED>                                                 0
<COMMON>                                                1,249
<OTHER-SE>                                             64,348
<TOTAL-LIABILITY-AND-EQUITY>                          324,369
<SALES>                                               137,442
<TOTAL-REVENUES>                                      137,442
<CGS>                                                 100,369
<TOTAL-COSTS>                                         100,369
<OTHER-EXPENSES>                                        4,112
<LOSS-PROVISION>                                          384
<INTEREST-EXPENSE>                                      4,463
<INCOME-PRETAX>                                           (91)
<INCOME-TAX>                                              563
<INCOME-CONTINUING>                                      (732)
<DISCONTINUED>                                              0
<EXTRAORDINARY>                                             0
<CHANGES>                                                   0
<NET-INCOME>                                             (732)
<EPS-PRIMARY>                                           (0.06)
<EPS-DILUTED>                                           (0.06)
        

</TABLE>
*Product ingredient source information may be entitled to confidential treatment*
























*Product ingredient source information may be entitled to confidential treatment*













 

______________________________________________________________ 

Page is not included in this copy. 

Pages 82 through 83 are not included in this copy. 

_________________________________________________________________ 

The material not included contains the following type of 

information: 

_____ Identity of product inert ingredients. 

__ __ Identity of product impurities. 

__ __ Description of the product manufacturing process. 

__ __ Description of quality control procedures. 

__ __ Identity of the source of product ingredients. 

_____ Sales or other commercial/financial information. 

_____ A draft product label. 

__X__ The product confidential statement of formula. 

_____ Information about a pending registration action. 

__ __ FIFRA registration data. 

__ __ The document is a duplicate of page(s) _ . 

_____ The document is not responsive to the request. 

__ __ Internal deliberative information. 

__ __ Privileged attorney-client communication. 

__ __ Claimed Confidential by submitter upon submission to the 

 Agency.
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             APR-01-1996
<PERIOD-END>                               JUN-30-1996
<CASH>                                          15,091
<SECURITIES>                                         0
<RECEIVABLES>                                    3,912
<ALLOWANCES>                                        65
<INVENTORY>                                          0
<CURRENT-ASSETS>                                20,512
<PP&E>                                           1,685
<DEPRECIATION>                                     433
<TOTAL-ASSETS>                                  21,858
<CURRENT-LIABILITIES>                            2,857
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        16,530
<OTHER-SE>                                       2,005
<TOTAL-LIABILITY-AND-EQUITY>                    21,858
<SALES>                                          5,894
<TOTAL-REVENUES>                                 5,894
<CGS>                                                0
<TOTAL-COSTS>                                    3,510
<OTHER-EXPENSES>                                 2,134
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  16
<INCOME-PRETAX>                                    407
<INCOME-TAX>                                       107
<INCOME-CONTINUING>                                300
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       300
<EPS-PRIMARY>                                     0.02
<EPS-DILUTED>                                     0.02
        

</TABLE>
<PAGE>

Exhibit 11.1

                               OAKLEY, INC.

                 COMPUTATION OF EARNINGS PER COMMON SHARE
                (IN THOUSANDS EXCEPT FOR PER SHARE AMOUNTS)


                                                                 Year Ended
                                                              December 31, 1996
                                                            -------------------
Common Shares and common share equivalents:

Number of shares outstanding at beginning of period                71,400

Weighted average number of shares issued during the period            12

Weighted average shares issuable upon the exercise of common
  stock options net of shares assumed to be repurchased from
  proceeds obtained therefrom                                         404

Weighted average purchase of common shares                            (88)
                                                                --------------

Weighted average common and common equivalent shares
  at end of period                                                 71,728
                                                                --------------
                                                                --------------

Net income for primary net income per share                      $ 45,993

Net income per common and common equivalent shares               $   0.64
                                                                --------------
                                                                --------------


                                     46
PUBLIC LAW 115–309—DEC. 11, 2018 132 STAT. 4423 

LEGISLATIVE HISTORY—S. 3389: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

Sept. 25, considered and passed Senate. 

Nov. 27, considered and passed House. 

Æ 

Public Law 115–309 

115th Congress 

An Act 

To redesignate a facility of the National Aeronautics and Space Administration. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. REDESIGNATION OF NASA INDEPENDENT VERIFICATION 

AND VALIDATION FACILITY. 

(a) REDESIGNATION.—The National Aeronautics and Space 

Administration Independent Verification and Validation Facility 

in Fairmont, West Virginia, is hereby redesignated as the ‘‘Katherine Johnson Independent Verification and Validation Facility’’. 

(b) REFERENCES.—Any reference in any law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Katherine Johnson Independent Verification and Validation 

Facility’’. 

Approved December 11, 2018. 

Dec. 11, 2018 

[S. 3389] 


dkrause on DSKBC28HB2PROD with PUBLAWS
[Federal Register Volume 75, Number 39 (Monday, March 1, 2010)]
[Notices]
[Pages 9182-9184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4134]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary

[Transmittal No. 09-28]


36(b)(1) Arms Sales Notification

AGENCY: Defense Security Cooperation Agency, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing the unclassified text 
of a section 36(b)(1) arms sales notification to fulfill the 
requirements of section 155 of Public Law 104-164 dated 21 July 1996.

FOR FURTHER INFORMATION CONTACT: Ms. B. English, DSCA/DBO/CFM, (703) 
601-3740.

SUPPLEMENTARY INFORMATION: The following is a copy of a letter to the 
Speaker of the House of Representatives, Transmittals 09-28 with 
attached transmittal, and policy justification.

    Dated: February 23, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
BILLING CODE 5001-06-P
[GRAPHIC] [TIFF OMITTED] TN01MR10.000


[[Page 9183]]


[GRAPHIC] [TIFF OMITTED] TN01MR10.001


[[Page 9184]]


[GRAPHIC] [TIFF OMITTED] TN01MR10.002

[FR Doc. 2010-4134 Filed 2-26-10; 8:45 am]
BILLING CODE 5001-06-C
# C_2016165EN.01002101.xml

| 10.5.2016 | EN | Official Journal of the European Union | C 165/21 |
| --- | --- | --- | --- |

10.5.2016

EN

Official Journal of the European Union

C 165/21

---

Order of the General Court of 21 March 2016 — Salama v Council

(Case T-378/14) (1)

1

(2016/C 165/26)

Language of the case: French

The President of the Eighth Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 245, 28.7.2014.

1

---